
Anne Marie Carr
Director, Patents
Our specialist team are adept in dealing with the many ethical and regulatory challenges which are unique to the field, as well as navigating the constantly evolving legal landscape.
In an ever-evolving industry, pharmacology advancements are not just innovations, they transform lives. With over 50 years of experience of working in in-house intellectual property departments for various pharmaceutical companies, our team has a considerable depth of expertise in technical areas ranging from small molecules to biologics.

We utilise our extensive experience in this industry to provide a client-focused service, working with our clients to provide proactive, pragmatic and strategic advice across our full range of services taking into account the key commercial drivers behind each project.

Featured insight

Murgitroyd among eight firms to achieve gold across all categories in Financial Times ranking
EPO guidelines for examination: 2026 amendments & updates
Obtaining a patent: what makes an invention patentable?
Costs of applying for & maintaining a UK patent: a quick guide
Murgitroyd’s Helsinki Office Celebrates 15 Years
Patentability of AI inventions in Europe: Life Sciences, Chemical and Biotechnology inventions
Supplementary Protection Certificates (SPCs): What You Need to Know About the 2025 Changes
Applications of Generative AI in Drugs Development and Materials Discovery: IP Considerations
Retroactive Santen Rocks the SPC Landscape: Key Takeaways for Pharmaceutical Companies
Clouds on the horizon – AI in treating diseases
Merck v Mylan — can a presumption of invalidity be a defence for infringement?
Compulsory licences in times of crisis
Protect breakthroughs in pharmaceuticals from drug formulation to clinical methods. Our IP team ensures your advancements are safeguarded.